Take a look at our previous reports:

Equity components of the remuneration

Subscription rights awarded, exercised or expired

In 2021, we issued three subscription right plans for the benefit of employees of the group and of management board members: Subscription Right Plan 2021 BE, Subscription Right Plan 2021 RMV and Subscription Right Plan 2021 ROW. The management board members were offered new subscription rights under Subscription Right Plan 2021 BE, subject to acceptance. Subscription rights is the new term for instruments formerly referred to as “warrants” under the new Belgian Companies Code. The final number of accepted subscription rights under Subscription Right Plan 2021 BE was enacted by notary deeds of 2 July 2021 and 18 August 2021. The table below sets forth the numbers of subscription rights offered and accepted by each management board member in 2021 under Subscription Right Plan 2021 BE.

The main characteristics of the subscription right plans offered to the management board members are as follows:

  • The subscription rights are offered for no consideration;
  • The subscription rights typically have a lifetime of eight years and a vesting period of three years after the year of grant;
  • Good and bad leaver rules apply in case of termination prior to the end of the vesting period; and
  • The subscription rights are not transferable.

Under Subscription Right Plan 2021 BE, the subscription rights have a lifetime of eight years and an exercise price of €64.76. Each subscription right gives the right to subscribe for one new Galapagos share. For all the beneficiaries under the Subscription Right Plan 2021 BE, the subscription rights vest only and fully on the first day of the fourth calendar year following the calendar year in which the grant was made. The subscription rights can in principle not be exercised prior to 1 January 2025. The table below sets forth the main characteristics for subscription right plans issued during previous years.

As from 1 January 2020, Galapagos no longer grants any subscription rights to supervisory board members, taking into account the stricter rules of the Belgian Companies Code and provision 7.6 of the 2020 Code, which stipulates that non-executive directors should not be entitled to receive stock options. Prior to 2020, supervisory board members were granted subscription rights and hence the table below also contains disclosures for supervisory board members.

No subscription rights expired for management board or supervisory board members in 2021.

The table below sets forth the subscription rights outstanding and exercisable per 31 December 2021 for the management board and supervisory board members, the subscription rights awarded to the management board members during 2021 and exercised by the management board or supervisory board members in 2021, including for our former CSO Dr. Wigerinck:

 

Plan(1)

Grant date

Vesting period

Exercise period

Exercise price

Number of SRs out­standing per 31/12/2021

Number of SRs exer­cisable per 31/12/2021

SRs offered & accepted during 2021

SRs exercised during 2021

SRs expired in 2021

Supervisory board members

Dr. Rasjesh Parekh

WP 2017

30/08/2017

36 months
1/36 per month

01/01/2021 – 16/05/2025

€ 80.57

15,000

15,000

 

 

0

WP 2018

24/08/2018

36 months
1/36 per month

01/01/2022 – 18/04/2026

€ 79.88

15,000

 

 

 

0

WP 2019

12/07/2019

36 months
1/36 per month

01/01/2023 – 10/04/2027

€ 95.11

15,000

 

 

 

0

Mr. Howard Rowe

WP 2014

25/07/2014

36 months
1/36 per month

01/01/2018 – 24/07/2022

€ 14.54

2,520

2,520

 

 

0

WP 2015

30/04/2015

36 months
1/36 per month

01/01/2019 – 29/04/2023

€ 28.75

2,520

2,520

 

 

0

WP 2015.B

02/03/2016

36 months
1/36 per month

02/03/2019 – 21/12/2023

€ 49.00

7,500

7,500

 

 

0

WP 2016

16/08/2016

36 months
1/36 per month

01/01/2020 – 31/05/2024

€ 46.10

7,500

7,500

 

 

0

WP 2017

30/08/2017

36 months
1/36 per month

01/01/2021 – 16/05/2025

€ 80.57

7,500

7,500

 

 

0

WP 2018

24/08/2018

36 months
1/36 per month

01/01/2022 – 18/04/2026

€ 79.88

7,500

 

 

 

0

WP 2019

12/07/2019

36 months
1/36 per month

01/01/2023 – 10/04/2027

€ 95.11

7,500

 

 

 

0

Ms. Katrine Bosley

WP 2015

30/04/2015

36 months
1/36 per month

01/01/2019 – 29/04/2023

€ 28.75

2,520

2,520

 

 

0

WP 2015.B

02/03/2016

36 months
1/36 per month

02/03/2019 – 21/12/2023

€ 49.00

7,500

7,500

 

 

0

WP 2016

16/08/2016

36 months
1/36 per month

01/01/2020 – 31/05/2024

€ 46.10

7,500

7,500

 

 

0

WP 2017

30/08/2017

36 months
1/36 per month

01/01/2021 – 16/05/2025

€ 80.57

7,500

7,500

 

 

0

WP 2018

24/08/2018

36 months
1/36 per month

01/01/2022 – 18/04/2026

€ 79.88

7,500

 

 

 

0

WP 2019

12/07/2019

36 months
1/36 per month

01/01/2023 – 10/04/2027

€ 95.11

7,500

 

 

 

0

Dr. Mary Kerr

WP 2017

30/08/2017

36 months
1/36 per month

01/01/2021 – 16/05/2025

€ 80.57

7,500

7,500

 

 

0

WP 2018

24/08/2018

36 months
1/36 per month

01/01/2022 – 18/04/2026

€ 79.88

7,500

 

 

 

0

WP 2019

12/07/2019

36 months
1/36 per month

01/01/2023 – 10/04/2027

€ 95.11

7,500

 

 

 

0

Mr. Peter Guenter

WP 2019

12/07/2019

36 months
1/36 per month

01/01/2023 – 10/04/2027

€ 95.11

7,500

 

 

 

0

Dr. Elisabeth Svanberg

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Dr. Linda Higgins

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Mr. Daniel O'Day

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Management board members

Mr. Onno van de Stolpe

WP 2013

29/07/2013

36 months
1/36 per month

01/01/2017 – 15/05/2021

€ 19.38

0

0

 

41,874

0

WP 2014

14/10/2014

36 months
1/36 per month

01/01/2018 – 24/07/2022

€ 14.54

100,000

100,000

 

 

0

WP 2015

29/06/2015

36 months
1/36 per month

01/01/2019 – 29/04/2023

€ 28.75

100,000

100,000

 

 

0

WP 2015.B

02/03/2016

36 months
1/36 per month

02/03/2019 – 21/12/2023

€ 49.00

100,000

100,000

 

 

0

WP 2016

31/07/2016

36 months
1/36 per month

01/01/2020 – 31/05/2024

€ 46.10

100,000

100,000

 

 

0

WP 2017

30/08/2017

36 months
1/36 per month

01/01/2021 – 16/05/2025

€ 80.57

100,000

100,000

 

 

0

WP 2018

18/06/2018

36 months
1/36 per month

01/01/2022 – 18/04/2026

€ 79.88

100,000

 

 

 

0

WP 2019

12/07/2019

36 months
1/36 per month

01/01/2023 – 10/04/2027

€ 95.11

100,000

 

 

 

0

SR Plan 2020

16/06/2020

100% 3rd year
after year of grant
01/01/2024

01/01/2024 – 17/04/2028

€ 168.42

85,000

 

 

 

0

SR Plan 2021 BE

18/08/2021

100% 3rd year
after year of grant
01/01/2025

01/01/2025 – 30/04/2029

€ 64.76

85,000

 

85,000

 

0

Mr. Bart Filius

WP 2017

30/08/2017

100% 3rd year
after year of grant
01/01/2021

01/01/2021 – 16/05/2025

€ 80.57

60,000

60,000

 

 

0

WP 2018

18/06/2018

100% 3rd year
after year of grant
01/01/2022

01/01/2022 – 18/04/2026

€ 79.88

80,000

 

 

 

0

WP 2019

12/07/2019

100% 3rd year
after year of grant
01/01/2023

01/01/2023 – 10/04/2027

€ 95.11

65,000

 

 

 

0

SR Plan 2020

16/06/2020

100% 3rd year
after year of grant
01/01/2024

01/01/2024 – 17/04/2028

€ 168.42

50,000

 

 

 

0

SR Plan 2021 BE

18/08/2021

100% 3rd year
after year of grant
01/01/2025

01/01/2025 – 30/04/2029

€ 64.76

50,000

 

50,000

 

0

Dr. Andre Hoekema

WP 2014

14/10/2014

100% 3rd year
after year of grant
01/01/2018

01/01/2018 – 24/07/2022

€ 14.54

10,000

10,000

 

20,000

0

WP 2015

29/06/2015

100% 3rd year
after year of grant
01/01/2019

01/01/2019 – 29/04/2023

€ 28.75

30,000

30,000

 

 

0

WP 2015.B

02/03/2016

100% 3rd year
after year of grant
02/03/2019

02/03/2019 – 21/12/2023

€ 49.00

40,000

40,000

 

 

0

WP 2016

31/07/2016

100% 3rd year
after year of grant
01/01/2020

01/01/2020 – 31/05/2024

€ 46.10

55,000

55,000

 

 

0

WP 2017

30/08/2017

100% 3rd year
after year of grant
01/01/2021

01/01/2021 – 16/05/2025

€ 80.57

60,000

60,000

 

 

0

WP 2018

18/06/2018

100% 3rd year
after year of grant
01/01/2022

01/01/2022 – 18/04/2026

€ 79.88

50,000

 

 

 

0

WP 2019

12/07/2019

100% 3rd year
after year of grant
01/01/2023

01/01/2023 – 10/04/2027

€ 95.11

50,000

 

 

 

0

SR Plan 2020

16/06/2020

100% 3rd year
after year of grant
01/01/2024

01/01/2024 – 17/04/2028

€ 168.42

30,000

 

 

 

0

SR Plan 2021 BE

18/08/2021

100% 3rd year
after year of grant
01/01/2025

01/01/2025 – 30/04/2029

€ 64.76

30,000

 

30,000

 

0

Dr. Piet Wigerinck

WP 2015.B

02/03/2016

100% 3rd year
after year of grant
02/03/2019

02/03/2019 – 21/12/2023

€ 49.00

35,000

35,000

 

5,000

0

WP 2016

16/08/2016

100% 3rd year
after year of grant
01/01/2020

01/01/2020 – 31/05/2024

€ 46.10

60,000

60,000

 

 

0

WP 2017

30/08/2017

100% 3rd year
after year of grant
01/01/2021

01/01/2021 – 16/05/2025

€ 80.57

60,000

60,000

 

 

0

WP 2018

18/06/2018

100% 3rd year
after year of grant
01/01/2022

01/01/2022 – 18/04/2026

€ 79.88

60,000

 

 

 

0

WP 2019

12/07/2019

100% 3rd year
after year of grant
01/01/2023

01/01/2023 – 10/04/2027

€ 95.11

50,000

 

 

 

0

SR Plan 2020

16/06/2020

100% 3rd year
after year of grant
01/01/2024

01/01/2024 – 17/04/2028

€ 168.42

40,000

 

 

 

0

SR Plan 2021 BE

02/07/2021

100% 3rd year
after year of grant
01/01/2025

01/01/2025 – 30/04/2029

€ 64.76

40,000

 

40,000

 

0

Dr. Walid Abi-Saab

WP 2016.B

06/04/2017

100% 3rd year
after year of grant
06/04/2020

06/04/2020 – 19/01/2025

€ 62.50

10,000

10,000

 

 

0

WP 2017

30/08/2017

100% 3rd year
after year of grant
01/01/2021

01/01/2021 – 16/05/2025

€ 80.57

45,000

45,000

 

 

0

WP 2018

18/06/2018

100% 3rd year
after year of grant
01/01/2022

01/01/2022 – 18/04/2026

€ 79.88

60,000

 

 

 

0

WP 2019

12/07/2019

100% 3rd year
after year of grant
01/01/2023

01/01/2023 – 10/04/2027

€ 95.11

50,000

 

 

 

0

SR Plan 2020

23/06/2020

100% 3rd year
after year of grant
01/01/2024

01/01/2024 – 17/04/2028

€ 168.42

40,000

 

 

 

0

SR Plan 2021 BE

18/08/2021

100% 3rd year
after year of grant
01/01/2025

01/01/2025 – 30/04/2029

€ 64.76

40,000

 

40,000

 

0

Mr. Michele Manto

WP 2017

30/08/2017

100% 3rd year
after year of grant
01/01/2021

01/01/2021 – 16/05/2025

€ 80.57

60,000

60,000

 

 

0

WP 2018

18/06/2018

100% 3rd year
after year of grant
01/01/2022

01/01/2022 – 18/04/2026

€ 79.88

30,000

 

 

 

0

WP 2019

12/07/2019

100% 3rd year
after year of grant
01/01/2023

01/01/2023 – 10/04/2027

€ 95.11

40,000

 

 

 

0

SR Plan 2020

16/06/2020

100% 3rd year
after year of grant
01/01/2024

01/01/2024 – 17/04/2028

€ 168.42

30,000

 

 

 

0

SR Plan 2021 BE

02/07/2021

100% 3rd year
after year of grant
01/01/2025

01/01/2025 – 30/04/2029

€ 64.76

30,000

 

30,000

 

0

(1)

Warrant Plan (WP) and Subscription Rights Plan (SR Plan)

At the end of 2021, Mr. Onno van de Stolpe held 438,889 shares of Galapagos NV and 870,000 subscription rights, Mr. Bart Filius held 25,000 shares and 305,000 subscription rights, Dr. Walid Abi-Saab held 2,500 shares and 245,000 subscription rights, Dr. Andre Hoekema held 42,857 shares and 355,000 subscription rights, and Mr. Michele Manto held 1,000 shares and 190,000 subscription rights.

RSUs offered to, vested or expired for the management board members

In 2021, the management board were offered new RSUs under 2021 RSU Annual Long-Term Incentive Plan and the 2021 RSU Retention Plan, subject to acceptance. The members of the management board accepted all RSUs offered to them, except for two management board members who did not accept their grant under the 2021 RSU Annual Long-Term Incentive Plan. The grant under the 2021 RSU Annual Long-Term Incentive Plan is the long-term portion of the bonus for 2020 and this RSU grant will vest in full three years after the offer date. The grant under the 2021 RSU Retention Plan has a four-year vesting period, with 25% vesting each year and a first vesting date on 1 May 2022. The RSUs are not transferable. The table below sets forth the total number of RSUs offered to each management board member during 2021: Mr. Onno van de Stolpe: 63,830 RSUs, Mr. Bart Filius: 62,730 RSUs, Dr. Piet Wigerinck: 835 RSUs, Dr. Walid Abi-Saab: 44,038 RSUs, Dr. Andre Hoekema: 52,312 RSUs and Mr. Michele Manto: 31,694 RSUs.

The main characteristics of the RSU plans for the management board members are as follows:

  • The RSUs are offered for no consideration;
  • Three or four year vesting periods apply, as set forth per plan in the table below;
  • In case of termination of service before the vesting date, forfeiture rules apply.

Each RSU represents the right to receive, at Galapagos’ discretion, one Galapagos share or a payment in cash of an amount equivalent to the volume-weighted average price of the Galapagos share on Euronext Brussels over the 30-calendar day period preceding the relevant vesting date. However, in respect of management board members, any vesting prior to the third anniversary of the offer date will always give rise to a payment in cash rather than a delivery of shares as an incentive.

No RSUs expired during financial year 2021. The table below sets forth the main characteristics of RSU plans issued to the management board members in 2019, 2020 and 2021, the number of RSUs awarded to each management board member under the respective RSU Plan, and the number of RSUs vested and paid out to each management board member during 2021, including for our former CSO, Dr. Wigerinck:

Management board member

Plan

Offer date

Vesting period

Vesting date

Number of RSUs offered

RSUs vested during 2021

Mr. Onno van de Stolpe

Plan 2019.I

16/10/2019

100% three years after offer date

16/10/2022

15,000

 

Plan 2019.II

16/10/2019

25% / year
Four-year vesting period

01/05/2020
01/05/2021
01/05/2022
01/05/2023

25,606

6,401

Plan 2019.III

16/10/2019

50% two years after offer date
50% three years after offer date

16/10/2021
16/10/2022

16,922

8,461

Plan 2020.I

06/05/2020

100% three years after offer date

06/05/2023

2,392

 

Plan 2020.II

06/05/2020

25% / year
Four-year vesting period

01/05/2021
01/05/2022
01/05/2023
01/05/2024

15,925

3,981

Plan 2021.I

05/05/2021

100% three years after offer date

05/05/2024

2,111

 

Plan 2021.IV

24/09/2021

25% / year
Four-year vesting period

01/05/2022
01/05/2023
01/05/2024
01/05/2025

61,719

 

Mr. Bart Filius

Plan 2019.I

16/10/2019

100% three years after offer date

16/10/2022

5,000

 

Plan 2019.II

16/10/2019

25% / year
Four-year vesting period

01/05/2020
01/05/2021
01/05/2022
01/05/2023

17,924

4,481

Plan 2019.III

16/10/2019

50% two years after offer date
50% three years after offer date

16/10/2021
16/10/2022

16,922

8,461

Plan 2020.I

06/05/2020

100% three years after offer date

06/05/2023

1,452

 

Plan 2020.II

06/05/2020

25% / year
Four-year vesting period

01/05/2021
01/05/2022
01/05/2023
01/05/2024

11,148

2,787

Plan 2021.I

05/05/2021

100% three years after offer date

05/05/2024

1,011

 

Plan 2021.IV

24/09/2021

25% / year
Four-year vesting period

01/05/2022
01/05/2023
01/05/2024
01/05/2025

61,719

 

Dr. Andre Hoekema

Plan 2019.I

16/10/2019

100% three years after offer date

16/10/2022

3,000

 

Plan 2019.III

16/10/2019

50% two years after offer date
50% three years after offer date

16/10/2021
16/10/2022

16,922

8,461

Plan 2020.I

06/05/2020

100% three years after offer date

06/05/2023

832

 

Plan 2021.I

05/05/2021

100% three years after offer date

05/05/2024

879(1)

 

Plan 2021.IV

24/09/2021

25% / year
Four-year vesting period

01/05/2022
01/09/2022(2)
01/05/2024
01/05/2025

51,433

 

Dr. Piet Wigerinck

Plan 2019.I

16/10/2019

100% three years after offer date

16/10/2022

5,000

 

Plan 2019.II

16/10/2019

25% / year
Four-year vesting period

01/05/2020
01/05/2021
01/05/2022
01/05/2023

17,924

4,481

Plan 2019.III

16/10/2019

50% two years after offer date
50% three years after offer date

16/10/2021
16/10/2022

10,153

5,076

Plan 2020.I

06/05/2020

100% three years after offer date

06/05/2023

932

 

Plan 2020 II.

06/05/2020

25% / year
Four-year vesting period

01/05/2021
01/05/2022
01/05/2023
01/05/2024

11,148

2,787

Plan 2021.I

05/05/2021

100% three years after offer date

05/05/2024

835(3)

 

Dr. Walid Abi-Saab

Plan 2019.I

16/10/2019

100% three years after offer date

16/10/2022

5,000

 

Plan 2019.II

16/10/2019

25% / year
Four-year vesting period

01/05/2020
01/05/2021
01/05/2022
01/05/2023

17,924

4,481

Plan 2019.III

16/10/2019

50% two years after offer date
50% three years after offer date

16/10/2021
16/10/2022

10,153

5,076

Plan 2020.I

06/05/2020

100% three years after offer date

06/05/2023

932

 

Plan 2020.II

06/05/2020

25% / year
Four-year vesting period

01/05/2021
01/05/2022
01/05/2023
01/05/2024

11,148

2,787

Plan 2021.I

05/05/2021

100% three years after offer date

05/05/2024

835

 

Plan 2021.IV

24/09/2021

25% / year
Four-year vesting period

01/05/2022
01/05/2023
01/05/2024
01/05/2025

43,203

 

Mr. Michele Manto

Plan 2019.II

16/10/2019

25% / year
Four-year vesting period

01/05/2020
01/05/2021
01/05/2022
01/05/2023

5,121

1,280

Plan 2020.I

06/05/2020

100% three years after offer date

06/05/2023

612

 

Plan 2020.II

06/05/2020

25% / year
Four-year vesting period

01/05/2021
01/05/2022
01/05/2023
01/05/2024

5,308

1,327

Plan 2021.I

05/05/2021

100% three years after offer date

05/05/2024

835

 

Plan 2021.IV

24/09/2021

25% / year
Four-year vesting period

01/05/2022
01/05/2023
01/05/2024
01/05/2025

30,859

 

(1)

Dr. Andre Hoekema did not accept his offer under the 2021.I RSU Plan.

(2)

Upon substantiated recommendation of the remuneration and nomination committee, the supervisory board approved a deviation of the vesting rules under the RSU Plan 2021.IV. The second vesting of 25% of the RSU grant under the aforementioned plan (corresponding with 12,858 RSUs) will occur earlier than under the normal plan rules.

(3)

Dr. Piet Wigerinck did not accept his offer under the 2021.I RSU Plan.

Pursuant to the terms and conditions of the RSU plans all unvested RSUs of Dr. Piet Wigerinck, as set out in the table above, became null and void on his termination date, 30 November 2021. Reference is made to the one-time lump-sum payment as compensation for his unvested outstanding RSUs as set out in the section on severance payments for departing management board members.

In 2022, as part of the management board’s long-term variable remuneration, a number of RSUs equivalent to the 2021 short-term cash bonuses (based on the average share price of the Galapagos share on Euronext Amsterdam during the month of April 2022) will be granted to the management board members under the 2022 RSU Annual Long-Term Incentive Plan (i.e. the long-term portion of the bonus for 2021), except to the retiring CEO.